Residency · Residency · Critical Care

Coagulopathy and Massive Transfusion

Coagulation Physiology Review

Cell-Based Model of Coagulation

The contemporary understanding of hemostasis has moved beyond the traditional intrinsic and extrinsic cascade model toward a cell-based model that more accurately reflects the physiological process of clot formation. This model describes coagulation as occurring in three overlapping phases on specific cellular surfaces.

The initiation phase begins on tissue factor (TF)-bearing cells, where the TF-Factor VIIa complex generates small amounts of thrombin (Factor IIa). This initial thrombin generation is insufficient to produce a stable clot but serves as the critical trigger for the next phase. During the amplification phase, the trace thrombin generated during initiation diffuses to the surface of nearby platelets, activating them and simultaneously activating Factors V, VIII, and XI on the platelet surface. This transforms the platelet from a resting state to a fully activated state with exposed phospholipid surfaces capable of supporting large-scale enzymatic complexes.

The propagation phase occurs on the surface of activated platelets, where two critical enzyme complexes assemble. The tenase complex (Factors VIIIa/IXa) generates Factor Xa, and the prothrombinase complex (Factors Va/Xa) produces a massive burst of thrombin. This thrombin burst converts fibrinogen to fibrin, and Factor XIIIa subsequently crosslinks fibrin strands to create a stable, mechanically robust clot.

Endogenous Anticoagulation

The coagulation system is tightly regulated by endogenous anticoagulant pathways that prevent excessive clot formation. Antithrombin III inhibits thrombin, Factor Xa, and Factor IXa, serving as the primary circulating anticoagulant. The protein C/S pathway provides another regulatory mechanism, in which activated protein C, using protein S as a cofactor, degrades Factors Va and VIIIa, thereby attenuating thrombin generation. Tissue factor pathway inhibitor (TFPI) inhibits the TF/VIIa complex, limiting the initiation phase. The fibrinolytic system, in which tissue plasminogen activator (tPA) converts plasminogen to plasmin, degrades fibrin and produces D-dimer as a breakdown product, ensuring that clots are eventually dissolved after their hemostatic function is fulfilled.

Coagulopathy in Critical Illness

Disseminated Intravascular Coagulation (DIC)

Disseminated intravascular coagulation represents a pathological state of systemic coagulation activation that produces paradoxically simultaneous microvascular thrombosis and hemorrhage. Widespread activation of the coagulation cascade leads to diffuse microvascular fibrin deposition, consuming clotting factors and platelets and depleting them below the levels necessary for effective hemostasis at sites of injury.

The most common cause is sepsis, accounting for 35 to 45 percent of cases, followed by major trauma, malignancy (particularly acute promyelocytic leukemia and mucin-secreting adenocarcinomas), obstetric emergencies, burns, and transfusion reactions. The ISTH DIC scoring system provides a standardized diagnostic framework based on platelet count, D-dimer level, prothrombin time prolongation, and fibrinogen level, with a score of 5 or greater indicating overt DIC (sensitivity 93 percent, specificity 98 percent).

Laboratory findings in established DIC include thrombocytopenia, prolonged PT and aPTT, markedly elevated D-dimer (greater than 10 times normal), low fibrinogen (below 150 mg/dL), and schistocytes on peripheral blood smear reflecting mechanical hemolysis from microangiopathic damage to red blood cells. Management centers on treating the underlying cause while providing supportive transfusion of FFP, platelets, and cryoprecipitate for fibrinogen levels below 150 mg/dL in patients with active bleeding. The role of anticoagulation with heparin is limited to predominantly thrombotic presentations such as purpura fulminans or large vessel thrombosis and remains controversial.

Trauma-Induced Coagulopathy (TIC)

Trauma-induced coagulopathy is a distinct entity that develops rapidly and is present in 25 to 35 percent of severely injured patients on arrival to the emergency department, before any iatrogenic contributions. The endogenous component arises from tissue hypoperfusion, which activates protein C, promotes fibrinolysis, and consumes clotting factors. This is compounded by exogenous, iatrogenic factors that constitute the "lethal triad" of hypothermia, acidosis, and hemodilution.

Hypothermia below 34 degrees Celsius directly impairs enzymatic function of the coagulation cascade, with approximately a 10 percent reduction in activity for each degree below 37 degrees Celsius. Acidosis with pH below 7.2 profoundly impairs factor activity, with the Factor Va/Xa prothrombinase complex losing 50 percent of its activity at pH 7.0. Hemodilution from crystalloid and colloid resuscitation without concurrent blood product replacement progressively depletes circulating clotting factors and platelets. Hyperfibrinolysis, detectable by TEG or ROTEM, occurs in 2 to 5 percent of trauma patients but carries a mortality rate exceeding 60 percent, making it one of the most lethal manifestations of TIC.

Anticoagulant-Associated Coagulopathy

Reversal of anticoagulant therapy in the setting of life-threatening hemorrhage requires agent-specific approaches. For warfarin, 4-factor prothrombin complex concentrate (PCC) at 25 to 50 units/kg combined with vitamin K 10 mg IV is the preferred strategy, with a target of achieving INR below 1.5 within 30 minutes. Four-factor PCC is preferred over FFP because it provides faster, more predictable reversal with lower volume and without the need for ABO blood type matching.

For direct oral anticoagulants, specific antidotes are available. Idarucizumab at 5 g IV provides complete reversal of dabigatran, as demonstrated in the RE-VERSE AD trial with 100 percent reversal efficacy. Andexanet alfa, given as a 400 to 800 mg bolus plus infusion, reverses factor Xa inhibitors such as rivaroxaban and apixaban, with the ANNEXA-4 trial demonstrating 82 percent hemostatic efficacy. When specific antidotes are unavailable, 4-factor PCC at 50 units/kg is recommended, with activated PCC (FEIBA) as an alternative for dabigatran. For unfractionated heparin, protamine sulfate provides complete reversal at a dose of 1 mg per 100 units of heparin administered in the preceding 2 to 3 hours, with a maximum dose of 50 mg. LMWH is only partially reversed by protamine (approximately 60 percent), dosed at 1 mg per 1 mg of enoxaparin given in the last 8 hours.

<image>Cell-based coagulation model diagram with three phases shown as sequential panels around a platelet surface. Panel 1 (Initiation): tissue factor-bearing cell with TF/VIIa complex generating small amounts of Xa and thrombin (IIa), with arrows showing trace thrombin diffusing to platelet. Panel 2 (Amplification): platelet surface with thrombin activating factors V, VIII, and XI, and converting platelet from resting to activated state with pseudopodia. Panel 3 (Propagation): activated platelet surface showing tenase complex (VIIIa/IXa generating Xa) and prothrombinase complex (Va/Xa generating thrombin burst), leading to fibrinogen → fibrin conversion and XIIIa crosslinking. Below: disruption panel showing DIC pathways (excessive TF exposure, consumption) and trauma coagulopathy pathways (activated protein C, hyperfibrinolysis, lethal triad). Include standard coagulation tests mapped to the relevant phase (PT → initiation/propagation, aPTT → amplification/propagation, fibrinogen → terminal pathway).</image>

Viscoelastic Testing

Thromboelastography (TEG) and Rotational Thromboelastometry (ROTEM)

Viscoelastic testing with TEG or ROTEM has transformed the management of coagulopathy in trauma, cardiac surgery, and critical care. These point-of-care whole blood assays provide real-time assessment of the entire coagulation process, from initial clot formation through clot strength to fibrinolysis, in a single test performed at the bedside. Their principal advantage over conventional coagulation studies is turnaround time (15 to 20 minutes versus 45 to 60 minutes for standard laboratory tests) and their ability to assess aspects of coagulation not captured by traditional assays, including platelet function and fibrinolysis.

TEG Parameters

The TEG tracing generates several clinically actionable parameters. The R time (reaction time) represents the interval from test initiation to initial fibrin formation and reflects clotting factor activity, analogous to the PT and aPTT. A prolonged R time suggests clotting factor deficiency and indicates the need for FFP or prothrombin complex concentrate.

The K time and alpha angle reflect the rate of clot strengthening and are influenced by both fibrinogen and platelet activity. Maximum amplitude (MA) is perhaps the most clinically important parameter, representing maximal clot strength. It is determined primarily by platelet function (approximately 80 percent contribution) and fibrinogen (approximately 20 percent). A low MA indicates platelet dysfunction or thrombocytopenia and should be treated with platelet transfusion, with cryoprecipitate added if the fibrinogen component is also contributing.

LY30, the percentage of clot lysis at 30 minutes, is the critical parameter for detecting fibrinolysis. An LY30 exceeding 3 percent indicates clinically significant fibrinolysis requiring treatment with tranexamic acid.

ROTEM Parameters (Equivalent to TEG)

The ROTEM system provides equivalent information through different assay channels. EXTEM evaluates the extrinsic pathway (analogous to PT), reporting clotting time (CT), clot formation time (CFT), and maximum clot firmness (MCF). INTEM assesses the intrinsic pathway (analogous to aPTT). FIBTEM isolates the fibrinogen contribution by adding a platelet inhibitor, with an MCF below 10 mm indicating fibrinogen deficiency requiring cryoprecipitate or fibrinogen concentrate. APTEM adds an antifibrinolytic agent, and if the APTEM results correct an abnormal EXTEM pattern, this confirms fibrinolysis as the mechanism.

Goal-Directed Transfusion

Viscoelastic-guided transfusion algorithms have been demonstrated to reduce blood product usage by 30 to 50 percent in cardiac surgery and trauma compared to empiric transfusion strategies. The 2023 European guidelines recommend viscoelastic-guided transfusion for the management of major hemorrhage. The integration of TEG or ROTEM results with massive transfusion protocols enables targeted component therapy, directing specific products to specific deficits rather than relying on empiric ratio-based transfusion alone.

Massive Transfusion

Definition and Activation

Multiple definitions of massive transfusion exist, reflecting the challenge of capturing a dynamic process with a static definition. The classic definition is the administration of 10 or more units of packed red blood cells within 24 hours. A more clinically useful revised definition identifies massive transfusion as the administration of 3 or more units of pRBCs within 1 hour with anticipated ongoing need. The critical administration threshold (CAT) of 3 or more units within 1 hour has been shown to better predict mortality than the traditional 24-hour definition.

Activation of the massive transfusion protocol should be guided by clinical judgment supplemented by objective scoring tools. The ABC (Assessment of Blood Consumption) score identifies patients likely to require massive transfusion when 2 or more of the following are present: penetrating mechanism of injury, systolic blood pressure at or below 90 mmHg, heart rate at or above 120 bpm, and a positive FAST examination. The TASH score and shock index (heart rate divided by systolic blood pressure, concerning when greater than 1.0) provide additional predictive tools.

Damage Control Resuscitation Principles

Damage control resuscitation represents a paradigm shift in trauma and hemorrhagic shock management, emphasizing physiological optimization over anatomical restoration in the initial phase of care. Permissive hypotension targets a systolic blood pressure of 80 to 90 mmHg until surgical hemorrhage control is achieved, recognizing that aggressive blood pressure augmentation before source control promotes continued bleeding. The critical exception is traumatic brain injury, in which systolic blood pressure should be maintained above 100 mmHg to ensure adequate cerebral perfusion.

Crystalloid administration should be minimized, as hemodilution with crystalloid worsens coagulopathy by diluting circulating clotting factors and platelets. Blood products should be used early in the resuscitation, with balanced component therapy as the default strategy. Hypothermia must be aggressively prevented through warming of all intravenous fluids, the use of active warming devices, and maintaining a warm environment. Acidosis correction is primarily achieved through restoration of perfusion (i.e., stopping the bleeding), with sodium bicarbonate reserved for pH below 7.1. Calcium replacement to maintain ionized calcium above 1.1 mmol/L is essential, as the citrate preservative in stored blood products chelates calcium, producing hypocalcemia that impairs both coagulation and cardiac function.

PROPPR Trial (2015)

The PROPPR trial, the largest randomized trial of transfusion ratios in trauma, enrolled 680 patients requiring massive transfusion and randomized them to a 1:1:1 ratio (pRBC:FFP:platelets) versus a 1:1:2 ratio. The primary outcome of 24-hour and 30-day mortality did not differ significantly between groups. However, the 1:1:1 group achieved hemostasis more frequently (86 percent versus 78 percent) and experienced fewer deaths from exsanguination in the first 24 hours. These findings support balanced ratio transfusion as the standard of care for massive hemorrhage.

Tranexamic Acid (TXA)

Tranexamic acid is an antifibrinolytic agent that inhibits plasminogen activation, preventing clot breakdown. The CRASH-2 trial (2010) established its role in trauma, demonstrating that administration within 3 hours of injury reduced all-cause mortality from 16.0 percent to 14.5 percent (number needed to treat of 67). The dosing regimen is 1 g IV over 10 minutes followed by 1 g IV infused over 8 hours. The critical timing constraint cannot be overemphasized: late administration beyond 3 hours after injury actually increases mortality through prothrombotic harm. The WOMAN trial extended the evidence to obstetric hemorrhage, showing that TXA reduces death from postpartum bleeding when administered within 3 hours. Given its effectiveness, low cost, and wide availability, TXA should be incorporated into every massive transfusion protocol.

Fibrinogen Replacement

Fibrinogen is the first coagulation factor to reach critically low levels during hemorrhage, and maintaining adequate fibrinogen levels is essential for effective clot formation. The target during active hemorrhage is a fibrinogen concentration of 150 to 200 mg/dL, higher than the standard threshold of 100 mg/dL used in non-hemorrhagic settings.

Cryoprecipitate is the traditional source of fibrinogen replacement, with each unit containing approximately 250 mg of fibrinogen. A standard dose of a 10-unit pool raises fibrinogen by approximately 70 mg/dL. Fibrinogen concentrate (RiaSTAP) at 1 to 2 g IV offers the advantages of precise dosing, no thawing requirement, and lower infection risk, with the dose calculated as target fibrinogen increase (mg/dL) multiplied by weight (kg) divided by 1700. The CRYOSTAT-2 trial (2023) evaluated early high-dose cryoprecipitate in trauma and found improved fibrinogen levels but no mortality difference, though the trial was likely underpowered for this endpoint. ROTEM/TEG-guided fibrinogen replacement using FIBTEM MCF or TEG functional fibrinogen provides the most targeted approach to dosing.

<image>Massive transfusion protocol activation and management flowchart. Entry point: "Major hemorrhage identified — activate MTP." Phase 1 (first cooler): 6 units pRBC (type O, uncrossmatched), 6 units FFP, 1 unit apheresis platelets, TXA 1 g IV bolus. Phase 2 (repeat coolers every 15-30 min): continue 1:1:1 ratio, check labs after each round (CBC, PT/INR, fibrinogen, iCa, ABG, TEG/ROTEM if available). Guided correction: low fibrinogen (<150) → cryoprecipitate 10 units; low platelets (<50K) → platelets; prolonged PT/INR → FFP or PCC; hypocalcemia (iCa <1.1) → calcium gluconate 3 g IV; TEG LY30 >3% → TXA 1 g. Endpoints: hemorrhage controlled, hemodynamics stable, lactate clearing, normothermia. Deactivation criteria listed. Include blood bank communication pathway and specimen labeling requirements.</image>

Transfusion Medicine in the ICU

Red Blood Cell Transfusion

The evidence base for red blood cell transfusion thresholds in critical care is robust and consistently supports a restrictive strategy. The TRICC trial (1999) demonstrated that a restrictive threshold (hemoglobin trigger of 7 g/dL) was at least as effective as a liberal threshold (10 g/dL) and may have been superior in certain subgroups. The TRISS trial (2014) confirmed these findings specifically in patients with septic shock, showing no difference in 90-day mortality between restrictive (7 g/dL) and liberal (9 g/dL) strategies. The TITRe2 trial (2015) extended the evidence to cardiac surgery with similar findings. Current practice recommends transfusion at a hemoglobin threshold of 7 g/dL for most stable ICU patients, with a threshold of 8 g/dL considered for patients with acute coronary syndrome or symptomatic anemia. The critical exception is active hemorrhage, in which transfusion should be guided by hemodynamic stability and clinical assessment rather than arbitrary hemoglobin thresholds.

Platelet Transfusion

Platelet transfusion thresholds vary with the clinical scenario. For prevention of spontaneous hemorrhage, transfusion is indicated when the platelet count falls below 10,000/mcL. For most procedures, a threshold of 50,000/mcL is appropriate, while neurosurgical and ophthalmic procedures require a higher threshold of 100,000/mcL. During massive hemorrhage, platelets should be maintained above 50,000/mcL, with some protocols targeting above 100,000/mcL. One apheresis unit or a 6-pack of pooled platelets typically raises the platelet count by 30,000 to 50,000/mcL. Platelet refractoriness, defined as a failure to achieve the expected post-transfusion increment, should prompt consideration of HLA-matched platelets.

Fresh Frozen Plasma

Fresh frozen plasma contains all coagulation factors and is supplied in units of 200 to 250 mL. Indications include INR greater than 1.5 with active bleeding, massive transfusion, thrombotic thrombocytopenic purpura (as therapeutic plasma exchange), and warfarin reversal when PCC is unavailable. The typical dose is 10 to 15 mL/kg, corresponding to approximately 4 to 6 units. ABO-compatible plasma is required because it contains naturally occurring anti-A and anti-B antibodies.

Transfusion Complications

Transfusion-associated circulatory overload (TACO) is the most common serious transfusion complication, presenting as volume overload with pulmonary edema. Risk factors include renal failure, congestive heart failure, and rapid transfusion rates. Management involves diuretics, slowing or stopping the transfusion, and respiratory support with non-invasive ventilation or CPAP.

Transfusion-related acute lung injury (TRALI) is an immune-mediated complication characterized by bilateral pulmonary infiltrates and hypoxemia developing within 6 hours of transfusion in the absence of another cause. It is mediated by anti-HLA or anti-neutrophil antibodies in donor plasma. Unlike TACO, TRALI should not be treated with diuretics, as the mechanism is immunological capillary leak rather than volume overload; management is supportive with lung-protective ventilation. The incidence has decreased significantly since the implementation of mitigation strategies including the use of male-only plasma donors.

Acute hemolytic transfusion reactions from ABO incompatibility produce intravascular hemolysis, DIC, renal failure, and shock, demanding immediate cessation of the transfusion, aggressive intravenous fluid administration, and workup including repeat type and screen and direct antiglobulin testing. Febrile non-hemolytic reactions are the most common transfusion reaction overall, resulting from cytokine accumulation in stored products, and are generally self-limited. Citrate toxicity producing hypocalcemia is a predictable consequence of massive transfusion that requires monitoring and replacement of ionized calcium.

Key Clinical Pearls

• TEG/ROTEM-guided transfusion reduces blood product usage by 30-50% compared to empiric transfusion — implement viscoelastic testing in your MTP
• The lethal triad (hypothermia + acidosis + coagulopathy) must be aggressively prevented — warm fluids, minimize crystalloid, use balanced blood product ratios
• Tranexamic acid must be given within 3 hours of injury — late TXA (>3 hours) INCREASES mortality
• Calcium replacement is critical during massive transfusion — hypocalcemia (iCa <1.0 mmol/L) impairs coagulation and cardiac function; target iCa >1.1 mmol/L
• Restrictive transfusion strategy (Hb trigger 7 g/dL) is appropriate for most stable ICU patients — avoid unnecessary transfusion
• Fibrinogen is the first factor to reach critically low levels during hemorrhage — maintain >150-200 mg/dL with cryoprecipitate or fibrinogen concentrate
• Distinguish TACO from TRALI: TACO responds to diuretics (volume overload), TRALI does NOT (immunologic capillary leak)
• Always reverse anticoagulants early in life-threatening hemorrhage: 4-factor PCC for warfarin, idarucizumab for dabigatran, andexanet alfa for factor Xa inhibitors

References

1. Holcomb JB, Tilley BC, Baraniuk S, et al. Transfusion of plasma, platelets, and red blood cells in a 1:1:1 vs a 1:1:2 ratio and mortality in patients with severe trauma: the PROPPR randomized clinical trial. JAMA. 2015;313(5):471-482.
2. CRASH-2 Trial Collaborators. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2). Lancet. 2010;376(9734):23-32.
3. Hebert PC, Wells G, Blajchman MA, et al. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. N Engl J Med. 1999;340(6):409-417.
4. Gonzalez E, Moore EE, Moore HB, et al. Goal-directed hemostatic resuscitation of trauma-induced coagulopathy: a pragmatic randomized clinical trial comparing a viscoelastic assay to conventional coagulation assays. Ann Surg. 2016;263(6):1051-1059.
5. Spahn DR, Bouillon B, Cerny V, et al. The European guideline on management of major bleeding and coagulopathy following trauma: sixth edition. Crit Care. 2023;27(1):80.

Read this lecture as Markdown